Trigyn Technologies Ltd

As of November 17, 2025, Trigyn Technologies is considered very expensive and overvalued with a high PE ratio of 47.41, negative EV to EBIT, and poor financial metrics, including a low ROE of 0.64% and a year-to-date stock performance lagging at -31.06% compared to the Sensex's 8.72%.

Trigyn Techno. has seen a significant decline in net sales and profits from Mar'24 to Mar'25, with net sales dropping to 894.41 Cr from 1,279.66 Cr, and profit after tax falling to 12.94 Cr from 19.96 Cr. Despite these declines, total assets and cash reserves increased during the same period.

As of November 7, 2025, Trigyn Technologies is considered overvalued due to its negative PE ratio of -2396.24, an EV to EBITDA of -27.79, and a Price to Book Value of 0.30, significantly underperforming compared to peers like TCS and Infosys, and has a year-to-date return of -33.25% against the Sensex's 6.50%.

As of November 7, 2025, Trigyn Techno. is considered overvalued with a valuation grade shift to expensive, highlighted by a PE Ratio of -2396.24 and an EV to EBITDA of -27.79, significantly underperforming compared to peers like TCS and Infosys, and a year-to-date return of -33.25% against the Sensex's 6.50%.

As of November 7, 2025, Trigyn Techno is considered overvalued with a valuation grade shift to expensive, reflected by a PE ratio of -2396.24, an EV to EBITDA of -27.79, a low ROE of 1.64%, and a poor year-to-date return of -33.25%, significantly underperforming compared to peers like TCS and Infosys.

Trigyn Techno. will announce its results on 13 November 2025.

As of November 6, 2025, Trigyn Technologies is fairly valued despite a significant negative PE ratio of -2451.43 and low Price to Book Value of 0.31, but its poor return performance compared to peers and the Sensex suggests caution for potential investors.

As of 06-Nov, Trigyn Technologies Ltd's stock price is Rs 74.19, down 1.46%, and has fallen 3.61% over the past week. The stock is trading below all key moving averages, indicating a bearish trend, and has underperformed significantly compared to the benchmark Sensex, which has gained year-to-date.

As of November 4, 2025, Trigyn Techno. is considered overvalued with a PE ratio of -2487.77, an EV to EBITDA of -26.45, and a year-to-date return of -30.70%, significantly underperforming compared to peers like TCS and Infosys.

As of November 4, 2025, Trigyn Technologies is overvalued with a negative PE ratio of -2487.77 and an EV to EBITDA ratio of -26.45, significantly underperforming its peers like TCS and Infosys, and has a year-to-date return of -30.70% compared to the Sensex's 6.81%.

As of 28-Oct, Trigyn Technologies Ltd's stock price is declining at 75.88, down 0.82%, and has fallen 2.78% over the last two days. The stock is underperforming significantly compared to the market, with a yearly return of -30.70% and poor long-term growth metrics.

As of October 17, 2025, Trigyn Technologies is fairly valued despite troubling financial ratios and significant underperformance compared to peers and the Sensex, indicating ongoing operational challenges.

As of October 17, 2025, Trigyn Technologies is fairly valued despite a significant negative PE ratio of -2570.38, indicating profitability challenges compared to peers like TCS and Infosys, and has underperformed the Sensex with a year-to-date return of -28.40%.

As of October 17, 2025, Trigyn Technologies is fairly valued despite a negative PE ratio of -2570.38 and an EV to EBITDA of -25.25, indicating significant challenges and underperformance compared to peers like TCS and Infosys, as well as a year-to-date return of -28.40% against the Sensex's 7.44%.

As of 08-Oct, Trigyn Technologies Ltd's stock price has risen to Rs 81.50, up 2.48%, but has seen a significant drop in delivery volume by 84.93%. Despite a recent price increase, the stock is down 24.99% year-to-date, indicating challenges in sustaining this upward trend.